Pub Date : 2025-11-01DOI: 10.1016/j.canrad.2025.104765
Delphine Antoni , Emmanuel Mesny , Osman El Kabbaj , Stéphanie Josset , Kévin Quintin , Adrien Boue-Rafle , Agnès Tallet-Richard , Igor Latorzeff
We present the updated recommendations of the Société française de radiothérapie oncologique (the French Society for Radiation Oncology) on the indications and technical modalities of radiotherapy for brain metastases. The management of brain metastases represents a complex therapeutic challenge, due to the increase in patient life expectancy, technological advances in imaging and radiotherapy, specific and relevant prognostic classifications, the increased intracranial efficacy of certain systemic therapies and also the possible iterative irradiation sequences. The prevention of acute and late side effects is essential. Therapeutic strategies defined in a multidisciplinary manner are becoming increasingly personalized and must be rediscussed according to the evolution of the intracranial and extracranial disease.
{"title":"Radiotherapy for brain metastases: 2025 update","authors":"Delphine Antoni , Emmanuel Mesny , Osman El Kabbaj , Stéphanie Josset , Kévin Quintin , Adrien Boue-Rafle , Agnès Tallet-Richard , Igor Latorzeff","doi":"10.1016/j.canrad.2025.104765","DOIUrl":"10.1016/j.canrad.2025.104765","url":null,"abstract":"<div><div>We present the updated recommendations of the Société française de radiothérapie oncologique (the French Society for Radiation Oncology) on the indications and technical modalities of radiotherapy for brain metastases. The management of brain metastases represents a complex therapeutic challenge, due to the increase in patient life expectancy, technological advances in imaging and radiotherapy, specific and relevant prognostic classifications, the increased intracranial efficacy of certain systemic therapies and also the possible iterative irradiation sequences. The prevention of acute and late side effects is essential. Therapeutic strategies defined in a multidisciplinary manner are becoming increasingly personalized and must be rediscussed according to the evolution of the intracranial and extracranial disease.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104765"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.canrad.2025.104767
Youssef Ghannam , Romuald Le Scodan , Sofia Rivera , Youlia Kirova , David Pasquier , Christophe Hennequin , Céline Bourgier , Bruno Cutuli , Agnès Richard-Tallet
Adjuvant radiotherapy is a key component in the management of breast cancer. After breast-conserving surgery for invasive carcinoma, adjuvant irradiation is systematically recommended regardless of patient characteristics, as it reduces the risk of local recurrence and improves survival. A boost to the tumour bed is indicated for patients under 50 years of age. Partial breast irradiation may be considered as an alternative to whole-breast irradiation, but only in carefully selected and fully informed patients. For ductal carcinoma in situ, postoperative irradiation is also systematically recommended after lumpectomy. After mastectomy, chest wall irradiation is indicated for pT4 tumours or in the presence of nodal involvement; it may be individualized for pT3 or pN1 tumours. When neoadjuvant chemotherapy precedes mastectomy, radiotherapy is recommended if the initial tumour was classified as T3–T4 or if clinical or radiological nodal involvement was present prior to chemotherapy, indication which can be questioned in the absence of lymph node involvement on the surgical specimen, depending on the tumour subtype. Axillary irradiation is indicated based on nodal dissection findings and may be considered in cases of sentinel node involvement without dissection. Supraclavicular and infraclavicular nodal irradiation is recommended in cases of histologically proven axillary involvement, while internal mammary node irradiation should be evaluated individually, based on the benefit/risk balance, particularly due to potential cardiac toxicity. Moderate hypofractionation is now the standard for whole-breast irradiation after lumpectomy, regardless of patient profile, due to its equivalent efficacy compared to conventional fractionation. It is also feasible for chest wall irradiation. Furthermore, recent randomized trials have shown that moderate hypofractionation can be applied to nodal irradiation without increased toxicity. For whole-breast irradiation alone, ultra hypofractionation (26 Gy delivered in five fractions) has demonstrated non-inferiority to moderate hypofractionation. Target volume delineation for the breast with or without boost, chest wall, and nodal areas relies on clinical, surgical, pathological, and initial imaging data. Various techniques are available (three-dimensional conformal radiotherapy or intensity-modulated radiotherapy); the selected approach should optimize target coverage while respecting organ-at-risk constraints. Respiratory gating should be offered when it helps reduce exposure to organs at risk, particularly the heart. Adjuvant chemotherapy is generally not delivered concurrently with radiotherapy. Hormone therapy may be initiated before, during, or after irradiation.
{"title":"Radiotherapy of breast cancer: 2025 update","authors":"Youssef Ghannam , Romuald Le Scodan , Sofia Rivera , Youlia Kirova , David Pasquier , Christophe Hennequin , Céline Bourgier , Bruno Cutuli , Agnès Richard-Tallet","doi":"10.1016/j.canrad.2025.104767","DOIUrl":"10.1016/j.canrad.2025.104767","url":null,"abstract":"<div><div>Adjuvant radiotherapy is a key component in the management of breast cancer. After breast-conserving surgery for invasive carcinoma, adjuvant irradiation is systematically recommended regardless of patient characteristics, as it reduces the risk of local recurrence and improves survival. A boost to the tumour bed is indicated for patients under 50<!--> <!-->years of age. Partial breast irradiation may be considered as an alternative to whole-breast irradiation, but only in carefully selected and fully informed patients. For ductal carcinoma in situ, postoperative irradiation is also systematically recommended after lumpectomy. After mastectomy, chest wall irradiation is indicated for pT4 tumours or in the presence of nodal involvement; it may be individualized for pT3 or pN1 tumours. When neoadjuvant chemotherapy precedes mastectomy, radiotherapy is recommended if the initial tumour was classified as T3–T4 or if clinical or radiological nodal involvement was present prior to chemotherapy, indication which can be questioned in the absence of lymph node involvement on the surgical specimen, depending on the tumour subtype. Axillary irradiation is indicated based on nodal dissection findings and may be considered in cases of sentinel node involvement without dissection. Supraclavicular and infraclavicular nodal irradiation is recommended in cases of histologically proven axillary involvement, while internal mammary node irradiation should be evaluated individually, based on the benefit/risk balance, particularly due to potential cardiac toxicity. Moderate hypofractionation is now the standard for whole-breast irradiation after lumpectomy, regardless of patient profile, due to its equivalent efficacy compared to conventional fractionation. It is also feasible for chest wall irradiation. Furthermore, recent randomized trials have shown that moderate hypofractionation can be applied to nodal irradiation without increased toxicity. For whole-breast irradiation alone, ultra hypofractionation (26<!--> <!-->Gy delivered in five fractions) has demonstrated non-inferiority to moderate hypofractionation. Target volume delineation for the breast with or without boost, chest wall, and nodal areas relies on clinical, surgical, pathological, and initial imaging data. Various techniques are available (three-dimensional conformal radiotherapy or intensity-modulated radiotherapy); the selected approach should optimize target coverage while respecting organ-at-risk constraints. Respiratory gating should be offered when it helps reduce exposure to organs at risk, particularly the heart. Adjuvant chemotherapy is generally not delivered concurrently with radiotherapy. Hormone therapy may be initiated before, during, or after irradiation.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104767"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.canrad.2025.104776
Vincent Grégoire , Kévin Quintin , Florence Huguet , Pierre Boisselier , Ulrike Schick , Philippe Giraud , Laure Vieillevigne , Cyrus Chargari , Thomas Leroy , Yoann Pointreau , Pierre Blanchard
This article reviews the various exclusive or postoperative external radiotherapy and brachytherapy options for oropharyngeal squamous cell carcinoma. Dose levels, fractionation, and association with systemic treatments are presented. The need for neck node dissection following local treatment is discussed, as well as specificities for the management of p16-positive tumours. Guidelines for target volume selection and delineation are thoroughly elaborated.
{"title":"Management of oropharyngeal squamous cell carcinoma: 2025 update","authors":"Vincent Grégoire , Kévin Quintin , Florence Huguet , Pierre Boisselier , Ulrike Schick , Philippe Giraud , Laure Vieillevigne , Cyrus Chargari , Thomas Leroy , Yoann Pointreau , Pierre Blanchard","doi":"10.1016/j.canrad.2025.104776","DOIUrl":"10.1016/j.canrad.2025.104776","url":null,"abstract":"<div><div>This article reviews the various exclusive or postoperative external radiotherapy and brachytherapy options for oropharyngeal squamous cell carcinoma. Dose levels, fractionation, and association with systemic treatments are presented. The need for neck node dissection following local treatment is discussed, as well as specificities for the management of p16-positive tumours. Guidelines for target volume selection and delineation are thoroughly elaborated.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104776"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-16DOI: 10.1016/j.canrad.2025.104754
Fatima Zahra Bellefkih , Benjamin Vandendorpe , Kamel Debbi , Gabriele Coraggio , Nhu Hanh To , Luc Simon , Luc Ollivier , Youlia Kirova , Yazid Belkacémi
Haematological malignancies include a broad spectrum of diseases. The substantial progress made in systemic treatment over the last 20 years is reshaping the role of radiotherapy. Recent technological progress in imaging and radiotherapy has led to significant refinements in targets definition, sparing of organ at risk to reduce toxicity, thus ensuring that radiotherapy remains the cornerstone for several indications. We present the recommendations of the Société française de radiothérapie oncologique for radiotherapy of haematological malignancies, which continues to evolve rapidly in terms of therapeutic strategy.
{"title":"Radiotherapy for haematological malignancies: Current best practices and advancements","authors":"Fatima Zahra Bellefkih , Benjamin Vandendorpe , Kamel Debbi , Gabriele Coraggio , Nhu Hanh To , Luc Simon , Luc Ollivier , Youlia Kirova , Yazid Belkacémi","doi":"10.1016/j.canrad.2025.104754","DOIUrl":"10.1016/j.canrad.2025.104754","url":null,"abstract":"<div><div>Haematological malignancies include a broad spectrum of diseases. The substantial progress made in systemic treatment over the last 20<!--> <!-->years is reshaping the role of radiotherapy. Recent technological progress in imaging and radiotherapy has led to significant refinements in targets definition, sparing of organ at risk to reduce toxicity, thus ensuring that radiotherapy remains the cornerstone for several indications. We present the recommendations of the Société française de radiothérapie oncologique for radiotherapy of haematological malignancies, which continues to evolve rapidly in terms of therapeutic strategy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104754"},"PeriodicalIF":1.4,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145314249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-16DOI: 10.1016/j.canrad.2025.104757
Chloé Buchalet , Constance Golfier , Jean-Christophe Faivre , David Azria , Youlia Kirova , Ariane Lapierre , Igor Latorzeff , Céline Mirjolet , Christophe Hennequin , Thomas Leroy , Johann Marcel
The combination of radiotherapy and oncologic systemic treatments has become clinical routine. We publish the first edition of the French guidelines to summarize the opportunities and risks of these combinations, aiming to harmonize standard practices. We first review the radiobiological principles underlying these associations. We also describe combinations known to be toxic and that should be avoided. Finally, we provide guidelines on the optimal timing for combining radiotherapy with chemotherapies, hormone therapies, targeted therapies and immunotherapy. These data are available on the website https://www.radio-sync.com.
{"title":"Guidelines about radiotherapy and oncologic systemic treatments: Stop or continue?","authors":"Chloé Buchalet , Constance Golfier , Jean-Christophe Faivre , David Azria , Youlia Kirova , Ariane Lapierre , Igor Latorzeff , Céline Mirjolet , Christophe Hennequin , Thomas Leroy , Johann Marcel","doi":"10.1016/j.canrad.2025.104757","DOIUrl":"10.1016/j.canrad.2025.104757","url":null,"abstract":"<div><div>The combination of radiotherapy and oncologic systemic treatments has become clinical routine. We publish the first edition of the French guidelines to summarize the opportunities and risks of these combinations, aiming to harmonize standard practices. We first review the radiobiological principles underlying these associations. We also describe combinations known to be toxic and that should be avoided. Finally, we provide guidelines on the optimal timing for combining radiotherapy with chemotherapies, hormone therapies, targeted therapies and immunotherapy. These data are available on the website <span><span>https://www.radio-sync.com</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104757"},"PeriodicalIF":1.4,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145314270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<div><div>We present the update of the recommendations of the Société française de radiothérapie oncologique on radiotherapy for hypopharynx. Intensity-modulated radiotherapy is the gold standard treatment for hypopharynx cancers. Early T1 and T2 tumours can be treated by exclusive radiation or surgery followed by postoperative radiation in case of high recurrence risk. For locally advanced tumours requiring total pharyngolaryngectomy (T2 or T3) or with significant lymph nodes involvement, they can be treated by chemoradiation or by induction drugs followed by exclusive radiation. For T4 tumour, surgery must be proposed. Different fractionation schedules are possible: for 35 fractions, the curative dose is 70<!--> <!-->Gy (delivered at 2<!--> <!-->Gy per fraction) and prophylactic doses are 50 to 56<!--> <!-->Gy (delivered at 2<!--> <!-->Gy per fraction in case of sequential radiotherapy or 1.6<!--> <!-->Gy in case of simultaneous integrated boost radiotherapy; for 33 fractions, the curative dose is 69.96<!--> <!-->Gy (delivered at 2.12<!--> <!-->Gy per fraction) and the prophylactic dose is 52.8<!--> <!-->Gy (delivered at 1.6<!--> <!-->Gy per fraction in simultaneous integrated boost radiotherapy or 54<!--> <!-->Gy in 1.64<!--> <!-->Gy per fraction); for 30 fractions, curative dose is 66<!--> <!-->Gy (delivered at 2.2<!--> <!-->Gy per fraction) and prophylactic dose is 54<!--> <!-->Gy (delivered at 1.8<!--> <!-->Gy per fraction in simultaneous integrated boost radiotherapy. Doses over 2<!--> <!-->Gy per fraction can be delivered when chemotherapy is not used regarding potential larynx toxicity. Postoperatively, radiotherapy is used for locally advanced cancer with dose levels based on pathologic criteria, delivering 60 to 66<!--> <!-->Gy for R1 resection and 57.6 to 60<!--> <!-->Gy for complete resection in bed tumour; 50 to 66<!--> <!-->Gy in lymph nodes areas regarding extracapsular spread. Target volume delineation recommendations were based on guidelines cited in this article.</div></div><div><div>Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique concernant la radiothérapie du cancer de l’hypopharynx. La radiothérapie conformationnelle avec modulation d’intensité est le traitement de référence pour les cancers de l’hypopharynx. Les tumeurs de stade précoce (T1 et T2) peuvent être traitées soit par irradiation exclusive soit par chirurgie suivie d’une irradiation postopératoire en cas de risque élevé de récidive. Pour les tumeurs localement évoluées nécessitant une pharyngolaryngectomie totale (T2 ou T3) ou avec un envahissement ganglionnaire significatif, elles peuvent être prises en charge d’emblée par une chimioradiothérapie concomitante ou par une chimiothérapie d’induction suivie d’une radiothérapie exclusive. Pour les tumeurs de stade T4, la chirurgie doit être proposée. Différents schémas de fractionnement sont envisageables: en 35 fractions, la dose à visée curative est de 70<!-->
{"title":"Radiotherapy for hypopharynx cancers: 2025 update","authors":"Dylan Bocha , Julian Biau , Alexandre Coutte , Andrès Huertas , Nolwenn Delaby , Michel Lapeyre , Pierre Blanchard , Yoann Pointreau","doi":"10.1016/j.canrad.2025.104755","DOIUrl":"10.1016/j.canrad.2025.104755","url":null,"abstract":"<div><div>We present the update of the recommendations of the Société française de radiothérapie oncologique on radiotherapy for hypopharynx. Intensity-modulated radiotherapy is the gold standard treatment for hypopharynx cancers. Early T1 and T2 tumours can be treated by exclusive radiation or surgery followed by postoperative radiation in case of high recurrence risk. For locally advanced tumours requiring total pharyngolaryngectomy (T2 or T3) or with significant lymph nodes involvement, they can be treated by chemoradiation or by induction drugs followed by exclusive radiation. For T4 tumour, surgery must be proposed. Different fractionation schedules are possible: for 35 fractions, the curative dose is 70<!--> <!-->Gy (delivered at 2<!--> <!-->Gy per fraction) and prophylactic doses are 50 to 56<!--> <!-->Gy (delivered at 2<!--> <!-->Gy per fraction in case of sequential radiotherapy or 1.6<!--> <!-->Gy in case of simultaneous integrated boost radiotherapy; for 33 fractions, the curative dose is 69.96<!--> <!-->Gy (delivered at 2.12<!--> <!-->Gy per fraction) and the prophylactic dose is 52.8<!--> <!-->Gy (delivered at 1.6<!--> <!-->Gy per fraction in simultaneous integrated boost radiotherapy or 54<!--> <!-->Gy in 1.64<!--> <!-->Gy per fraction); for 30 fractions, curative dose is 66<!--> <!-->Gy (delivered at 2.2<!--> <!-->Gy per fraction) and prophylactic dose is 54<!--> <!-->Gy (delivered at 1.8<!--> <!-->Gy per fraction in simultaneous integrated boost radiotherapy. Doses over 2<!--> <!-->Gy per fraction can be delivered when chemotherapy is not used regarding potential larynx toxicity. Postoperatively, radiotherapy is used for locally advanced cancer with dose levels based on pathologic criteria, delivering 60 to 66<!--> <!-->Gy for R1 resection and 57.6 to 60<!--> <!-->Gy for complete resection in bed tumour; 50 to 66<!--> <!-->Gy in lymph nodes areas regarding extracapsular spread. Target volume delineation recommendations were based on guidelines cited in this article.</div></div><div><div>Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique concernant la radiothérapie du cancer de l’hypopharynx. La radiothérapie conformationnelle avec modulation d’intensité est le traitement de référence pour les cancers de l’hypopharynx. Les tumeurs de stade précoce (T1 et T2) peuvent être traitées soit par irradiation exclusive soit par chirurgie suivie d’une irradiation postopératoire en cas de risque élevé de récidive. Pour les tumeurs localement évoluées nécessitant une pharyngolaryngectomie totale (T2 ou T3) ou avec un envahissement ganglionnaire significatif, elles peuvent être prises en charge d’emblée par une chimioradiothérapie concomitante ou par une chimiothérapie d’induction suivie d’une radiothérapie exclusive. Pour les tumeurs de stade T4, la chirurgie doit être proposée. Différents schémas de fractionnement sont envisageables: en 35 fractions, la dose à visée curative est de 70<!--> ","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104755"},"PeriodicalIF":1.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-14DOI: 10.1016/j.canrad.2025.104756
Line Claude , Jordan Bouter , Farid Goudjil , Emmanuel Jouglar , Valentine Martin , Luc Ollivier , Marie Cantaloube , Laetitia Padovani , Anne Laprie , Groupe français de radiothérapie pédiatrique (the French group of paediatric radiotherapy)
A third of children with cancer receive radiotherapy as part of their initial treatment, which represents 800 paediatric irradiations per year in France, carried out in 15 specialized centres approved on the recommendations of the Institut national du cancer (the French national cancer institute). The treatment guidelines follow the recommendations of the Société francaise de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE; the French society for childhood cancers) or the French and European prospective protocols. The therapeutic indications, the technical and ballistic choices for complex cases are frequently discussed during bimonthly paediatric radiotherapy technical webconferences. With an overall survival being 80 % for all cancers combined, long-term toxicity logically becomes a major concern, making the treatments preparation complex. Irradiation methods include all the techniques currently available: intensity-modulated radiotherapy, stereotactic irradiation delivered in either standard or hypofractionated protocols, brachytherapy and proton therapy. We present the update of the recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) on the indications, the technical methods of realization and the organisation and the specificities of paediatric radiation oncology.
{"title":"Guide for paediatric radiotherapy procedures: 2025 update","authors":"Line Claude , Jordan Bouter , Farid Goudjil , Emmanuel Jouglar , Valentine Martin , Luc Ollivier , Marie Cantaloube , Laetitia Padovani , Anne Laprie , Groupe français de radiothérapie pédiatrique (the French group of paediatric radiotherapy)","doi":"10.1016/j.canrad.2025.104756","DOIUrl":"10.1016/j.canrad.2025.104756","url":null,"abstract":"<div><div>A third of children with cancer receive radiotherapy as part of their initial treatment, which represents 800 paediatric irradiations per year in France, carried out in 15 specialized centres approved on the recommendations of the Institut national du cancer (the French national cancer institute). The treatment guidelines follow the recommendations of the Société francaise de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE; the French society for childhood cancers) or the French and European prospective protocols. The therapeutic indications, the technical and ballistic choices for complex cases are frequently discussed during bimonthly paediatric radiotherapy technical webconferences. With an overall survival being 80 % for all cancers combined, long-term toxicity logically becomes a major concern, making the treatments preparation complex. Irradiation methods include all the techniques currently available: intensity-modulated radiotherapy, stereotactic irradiation delivered in either standard or hypofractionated protocols, brachytherapy and proton therapy. We present the update of the recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) on the indications, the technical methods of realization and the organisation and the specificities of paediatric radiation oncology.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104756"},"PeriodicalIF":1.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-13DOI: 10.1016/j.canrad.2025.104753
Cyrus Chargari , Anne Ducassou , Adrien Laville , François Lucia , Adeline Petit , Isabelle Flandin , Abel Cordoba , Sophie Renard , Sylvain Demontoy , Jean-Michel Hannoun-Lévi , Carole Lafond , Alexandre Escande
External beam radiotherapy and brachytherapy are major treatments in the management of cervical cancer. For early-stage tumours with local risk factors, brachytherapy is a preoperative option. Postoperative radiotherapy is indicated according to histopathological criteria. For locally advanced tumours, chemoradiation is the standard treatment, followed by brachytherapy boost which is not optional. We present the 2025 update of the recommendations of the Société française de radiothérapie oncologique (the French society of radiation oncology) on the indications and techniques for external beam radiotherapy and brachytherapy for cervical cancer.
{"title":"Radiotherapy and brachytherapy for cervical cancer: Recommendations of the Société française de radiothérapie oncologique","authors":"Cyrus Chargari , Anne Ducassou , Adrien Laville , François Lucia , Adeline Petit , Isabelle Flandin , Abel Cordoba , Sophie Renard , Sylvain Demontoy , Jean-Michel Hannoun-Lévi , Carole Lafond , Alexandre Escande","doi":"10.1016/j.canrad.2025.104753","DOIUrl":"10.1016/j.canrad.2025.104753","url":null,"abstract":"<div><div>External beam radiotherapy and brachytherapy are major treatments in the management of cervical cancer. For early-stage tumours with local risk factors, brachytherapy is a preoperative option. Postoperative radiotherapy is indicated according to histopathological criteria. For locally advanced tumours, chemoradiation is the standard treatment, followed by brachytherapy boost which is not optional. We present the 2025 update of the recommendations of the Société française de radiothérapie oncologique (the French society of radiation oncology) on the indications and techniques for external beam radiotherapy and brachytherapy for cervical cancer.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104753"},"PeriodicalIF":1.4,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-13DOI: 10.1016/j.canrad.2025.104752
Cyrus Chargari , Anne Ducassou , Julie Leblanc , François Lucia , Adeline Petit , Isabelle Flandin , Abel Cordoba , Caroline Lafond , Sophie Renard , Alexandre Escande
The first intent upfront treatment of endometrial cancer is surgery. External radiotherapy and brachytherapy, however, are important tools in adjuvant setting, according to histopathological risk factors for locoregional recurrence or in the event of an inoperable tumour. We present the 2025 update of the recommendations of the Société française de radiothérapie oncologique (SFRO; French society of radiation oncology) on the indications and technical methods of performing radiotherapy and brachytherapy for endometrial cancer.
{"title":"Radiotherapy for endometrial cancer: 2025 update","authors":"Cyrus Chargari , Anne Ducassou , Julie Leblanc , François Lucia , Adeline Petit , Isabelle Flandin , Abel Cordoba , Caroline Lafond , Sophie Renard , Alexandre Escande","doi":"10.1016/j.canrad.2025.104752","DOIUrl":"10.1016/j.canrad.2025.104752","url":null,"abstract":"<div><div>The first intent upfront treatment of endometrial cancer is surgery. External radiotherapy and brachytherapy, however, are important tools in adjuvant setting, according to histopathological risk factors for locoregional recurrence or in the event of an inoperable tumour. We present the 2025 update of the recommendations of the Société française de radiothérapie oncologique (SFRO; French society of radiation oncology) on the indications and technical methods of performing radiotherapy and brachytherapy for endometrial cancer.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104752"},"PeriodicalIF":1.4,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号